Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This case report details a 57-year-old woman with frontal fibrosing alopecia who developed hyperpigmentation after treatment with dutasteride and pimecrolimus, highlighting no previously reported hyperpigmentation association with this combination.

This report describes a 57-year-old woman with fibrosing alopecia in a pattern distribution, who experienced hair regrowth with combined treatment including hydroxychloroquine and other topical and oral therapies.

This study reported that both AGA and SD in Caucasian male patients showed overlapping histopathological features with FAPD, particularly perifollicular fibrosis and inflammation, complicating diagnosis.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found fractional carbon dioxide laser therapy effective in treating alopecia areata, both alone and with topical treatments, suggesting decorin's involvement in improving hair growth.

This report suggests a causal connection between hyaluronic acid filler injections and the development of xanthelasma, possibly through an inflammatory reaction that increases vascular permeability and LDL leakage.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This article outlines a treatment protocol for frontal fibrosing alopecia using finasteride or dutasteride and minoxidil, but reports no new clinical results.

This study found that applying ferrous ferric chloride skin lotions to newborn mice stimulated skin cell proliferation and differentiation, increased hair growth, and inhibited alopecia-related hair loss.

Mycophenolic acid may help hair growth, a combination treatment improves hair thickness in male hair loss, and early treatment of frontal fibrosing alopecia is important.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This study observed that antifungal treatment in fungal asthma patients led to a significant decrease in oral corticosteroid use, though the clinical importance remains unclear due to potential confounders.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

In this study, the researchers found that the picosecond pulsed alexandrite laser (PSAL) may be as effective and safe as the Q-switched alexandrite laser (QSAL) for treating freckles in Chinese patients.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

Channels stay open for 24 hours, making laser treatment potentially effective for hair loss.

This case report describes a family with autosomal dominant transmission of keratosis follicularis spinulosa decalvans, with observed treatment refractoriness in multiple topical and systemic therapies.

This article describes a previously unreported hair anomaly associated with facio-genito-popliteal syndrome and does not present new clinical results.

This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

In this study, fractional CO2 laser treatment for alopecia areata was found to significantly increase terminal hair and patient satisfaction compared to betamethasone valerate cream alone, highlighting its efficacy and safety both as a standalone and combined treatment.

This study found that RALF peptides, through liquid-liquid phase separation, form condensates with pectin and other proteins, playing a pivotal role in plant development and stress response regulation.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This study found that finasteride use was associated with significantly higher odds of obstructive sleep apnea and insomnia compared to other medications.